Document is current

Article History

Received: 16 November 2022

Accepted: 12 September 2023

First Online: 10 October 2023

Competing interests

: G.L.B. reports prior or active roles as a consultant/advisory board member for Boehinger Ingelheim, Adicet Bio, Aduro Biotech, AstraZeneca, BiolineRx, BioMarin Pharmaceuticals, Boehinger Ingelheim, Bristol-Myers Squibb, Cantargia, Cour Pharmaceuticals, Genmab, HiberCell, HotSpot Therapeutics, Incyte, Janssen, Legend Biotech, Merck, Monopteros, Molecular Partners, Nano Ghosts, Opsona, Pancreatic Cancer Action Network, Seagen, Shattuck Labs, and Verastem, and; reports receiving commercial research grants from Alligator Biosciences, Arcus, Bristol-Myers Squibb, Genmab, Gilead, Halozyme, HiberCell, Incyte, Janssen, Newlink, Novartis, and Verastem,. G.L.B. is an inventor of intellectual property (U.S. patent numbers 10,640,569 and 10,577,417) and recipient of royalties related to CAR T cells that is licensed by the University of Pennsylvania to Novartis and Tmunity Therapeutics. N.B., J.D., B.H. are employees of Hibercell, Inc. M.U. is a previous employee of Hibercell and current employee of OncXerna. N.B., J.D., B.H., M.U. are Hibercell stockholders. N.B., M.U. are an inventors of intellectual property that is licensed to Hibercell. M.U. holds OncXerna and Rigel stock. M.C. is an employee of Merck & Co., Inc and holds Merck stock. M.M.W. reports prior or active roles as a consultant for Nanology. The remaining authors declare no competing interests.